盟科药业-U
(688373)
| 流通市值：29.86亿 | | | 总市值：32.35亿 |
| 流通股本：6.06亿 | | | 总股本：6.56亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 42,059,686.69 | 141,772,692.05 | 103,985,283.24 | 66,969,753.09 |
| 营业收入 | 42,059,686.69 | 141,772,692.05 | 103,985,283.24 | 66,969,753.09 |
| 二、营业总成本 | 65,266,281.49 | 395,758,992.12 | 304,175,409.85 | 209,906,680.34 |
| 营业成本 | 6,054,924.55 | 21,531,489.53 | 15,722,882.44 | 10,189,199.84 |
| 税金及附加 | 185,044.08 | 538,153.25 | 410,641.1 | 339,228.53 |
| 销售费用 | 22,833,451.82 | 90,301,284.67 | 67,787,383.65 | 48,488,509.1 |
| 管理费用 | 5,749,037.06 | 62,425,407.79 | 41,201,162.32 | 29,846,478.5 |
| 研发费用 | 26,790,014.31 | 213,930,910.17 | 172,747,166.04 | 116,413,285.79 |
| 财务费用 | 3,653,809.67 | 7,031,746.71 | 6,306,174.3 | 4,629,978.58 |
| 其中:利息费用 | 4,259,133.18 | 12,892,331 | 9,541,983.59 | 6,323,076.82 |
| 其中:利息收入 | 389,103.61 | 2,406,534.46 | 2,151,170.27 | 1,902,760.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,500,262.84 | 6,490,192.45 | 6,052,443.15 | 4,261,022.11 |
| 资产处置收益 | - | 1,496.97 | 3,387.23 | 4,427.63 |
| 信用减值损失(新) | -57,749.35 | -232,245.96 | -267,337.96 | -305,646.54 |
| 其他收益 | 334,295.22 | 2,652,691.39 | 1,485,848.11 | 905,168.65 |
| 四、营业利润 | -21,429,786.09 | -245,074,165.22 | -192,915,786.08 | -138,071,955.4 |
| 加:营业外收入 | - | 500.02 | 500 | 500 |
| 减:营业外支出 | 50 | 491,864.63 | 491,864.63 | 487,264.63 |
| 五、利润总额 | -21,429,836.09 | -245,565,529.83 | -193,407,150.71 | -138,558,720.03 |
| 减:所得税费用 | 23,813.62 | -3,953,170.34 | 128,996.55 | 115,772.52 |
| 六、净利润 | -21,453,649.71 | -241,612,359.49 | -193,536,147.26 | -138,674,492.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -21,453,649.71 | -241,612,359.49 | -193,536,147.26 | -138,674,492.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -21,453,649.71 | -241,612,359.49 | -193,536,147.26 | -138,674,492.55 |
| 扣除非经常损益后的净利润 | -23,288,157.77 | -250,265,375.69 | -200,586,461.12 | -143,358,346.31 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | -0.37 | -0.3 | -0.21 |
| (二)稀释每股收益 | -0.03 | -0.37 | -0.3 | -0.21 |
| 八、其他综合收益 | -2,424,500.46 | -9,392,194.42 | -5,117,441.93 | -2,175,638.72 |
| 归属于母公司股东的其他综合收益 | -2,424,500.46 | -9,392,194.42 | -5,117,441.93 | -2,175,638.72 |
| 九、综合收益总额 | -23,878,150.17 | -251,004,553.91 | -198,653,589.19 | -140,850,131.27 |
| 归属于母公司股东的综合收益总额 | -23,878,150.17 | -251,004,553.91 | -198,653,589.19 | -140,850,131.27 |
| 公告日期 | 2026-04-29 | 2026-03-28 | 2025-10-28 | 2025-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |